A prospective study of docetaxel-associated pain syndrome
- 22.07.2017
- Original Article
Erschienen in:
- Verfasst von
- Nicholas Chiu
- Liying Zhang
- Rebecca Dent
- Angie Giotis
- Jenna van Draanen
- Daniela Gallo-Hershberg
- Leonard Chiu
- Ronald Chow
- Bo Angela Wan
- Mark Pasetka
- Jordan Stinson
- Erica Stacey
- Sunil Verma
- Henry Lam
- Edward Chow
- Carlo DeAngelis
- Erschienen in
- Supportive Care in Cancer | Ausgabe 1/2018
Abstract
Purpose
To investigate the natural history of taxane-associated acute pain syndrome (TAPS) in a docetaxel patient cohort and to examine the long-term manifestation of TAPS.
Patients and methods
For three consecutive treatment cycles, taxane-naive breast cancer patients completed diaries on days 1–7, 14, and 21 and telephone questionnaires 1, 3, 6, 9, and 12 months following treatment. Questionnaires to assess pain and interference were adapted from the Brief Pain Inventory. To examine the experience of arthralgia and myalgia as one syndrome, information on patient experiences with arthralgia or myalgia was elicited separately in order to determine how closely experiences of each toxicity correlated with each other. A ≥2 point increase from baseline was defined as an arthralgia or myalgia “pain flare,” and only those with “flare” were included in calculations of incidence.
Results
A total of 278 patients were accrued. Thirty-eight patients were omitted due to missing information, and 24 patients were omitted due to metastatic disease, for a total of 216 patients overall and 188 in the docetaxel cohort. A total of 74.5% of docetaxel patients experienced joint pain flare, and 78.2% experienced muscle pain flare at some point in the overall course of three treatment cycles. Joint and muscle pain peaked on days 4–5 for each cycle, and median pain severity for both joint and muscle pain was 4/10 during the 21-day period. Median onset of joint pain flare was 3 days for cycle 1 and 4 days for cycles 2 and 3, with an average median duration of 4 days. Median onset of muscle pain flare was 4 days for all three cycles, with a median duration of 4 days for cycles 1 and 2, and 5 days for cycle 3. Both joint and muscle pain persisted 1 year after treatment in approximately half of responding patients.
Conclusion
This study documents the significant incidence of TAPS in patients treated with docetaxel chemotherapy and shows a long-term persistence of the syndrome.
Anzeige
- Titel
- A prospective study of docetaxel-associated pain syndrome
- Verfasst von
-
Nicholas Chiu
Liying Zhang
Rebecca Dent
Angie Giotis
Jenna van Draanen
Daniela Gallo-Hershberg
Leonard Chiu
Ronald Chow
Bo Angela Wan
Mark Pasetka
Jordan Stinson
Erica Stacey
Sunil Verma
Henry Lam
Edward Chow
Carlo DeAngelis
- Publikationsdatum
- 22.07.2017
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Supportive Care in Cancer / Ausgabe 1/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339 - DOI
- https://doi.org/10.1007/s00520-017-3836-z
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
